ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.76
-0.42%
US Tech 100
21,373.60
-0.96%
S&P 500
6,098.96
-0.74%
US Dollar vs CAD
1.42
-0.29%
Bitcoin
97,142.75
0.53%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Omeros Corporation (OMER)

  7. Omeros Corporation (OMER) News

OMER

Omeros (OMER)

Omeros Corporation
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:OMER
DateTimeSourceHeadlineSymbolCompany
02/20/20258:15AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:OMEROmeros Corporation
02/20/20258:10AMBusiness WireOmeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMANASDAQ:OMEROmeros Corporation
02/14/20258:00AMBusiness WireOmeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem MeetingsNASDAQ:OMEROmeros Corporation
02/10/20258:00AMBusiness WireOmeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access ProgramNASDAQ:OMEROmeros Corporation
01/16/20258:25AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:OMEROmeros Corporation
01/16/20258:15AMBusiness WireOmeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary EndpointNASDAQ:OMEROmeros Corporation
12/19/20248:20AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:OMEROmeros Corporation
12/19/20248:15AMBusiness WireOmeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMANASDAQ:OMEROmeros Corporation
12/10/20247:45AMBusiness WireOmeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual MeetingNASDAQ:OMEROmeros Corporation
12/02/20247:45AMBusiness WireOmeros Corporation Announces Upcoming Presentations at ASH Annual MeetingNASDAQ:OMEROmeros Corporation
11/21/20248:15AMBusiness WireOmeros Corporation Provides Update on Progress Toward BLA ResubmissionNASDAQ:OMEROmeros Corporation
11/13/20243:08PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OMEROmeros Corporation
11/13/20243:06PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:OMEROmeros Corporation
11/13/20243:02PMBusiness WireOmeros Corporation Reports Third Quarter 2024 Financial ResultsNASDAQ:OMEROmeros Corporation
11/11/20243:11PMBusiness WireOmeros Corporation to Announce Third Quarter Financial Results on November 13, 2024NASDAQ:OMEROmeros Corporation
10/24/20247:45AMBusiness WireFDA Grants Rare Pediatric Disease Designation to Omeros’ MASP-3 Inhibitor Zaltenibart for Treatment of C3 GlomerulopathyNASDAQ:OMEROmeros Corporation
08/07/20243:08PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OMEROmeros Corporation
08/07/20243:06PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:OMEROmeros Corporation
08/07/20243:02PMBusiness WireOmeros Corporation Reports Second Quarter 2024 Financial ResultsNASDAQ:OMEROmeros Corporation
08/05/20243:02PMBusiness WireOmeros Corporation to Announce Second Quarter Financial Results on August 7, 2024NASDAQ:OMEROmeros Corporation
06/12/20243:48PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:OMEROmeros Corporation
06/07/20244:13PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OMEROmeros Corporation
06/07/20244:12PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OMEROmeros Corporation
06/07/20244:10PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OMEROmeros Corporation
06/07/20244:08PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OMEROmeros Corporation
06/07/20244:07PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OMEROmeros Corporation
06/07/20244:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OMEROmeros Corporation
06/04/20248:00AMBusiness WireOmeros Announces Webcast Details for Annual Meeting of ShareholdersNASDAQ:OMEROmeros Corporation
06/03/20248:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:OMEROmeros Corporation
06/03/20248:00AMBusiness WireOmeros Corporation Further Strengthens its Balance Sheet through Series of Financing Transactions Extending Maturity on a Majority of its Outstanding Debt into 2028NASDAQ:OMEROmeros Corporation
 Showing the most relevant articles for your search:NASDAQ:OMER

Your Recent History

BIT
VLT
Valtecne
USOTC
MHIVF
Invesque (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads